Viking Therapeutics Q2 2021 Earnings Report

Reported financial results for the second quarter of 2021 and provided a corporate update.

Key Takeaways

Viking Therapeutics reported a net loss of $15.4 million, or $0.20 per share, for the second quarter ended June 30, 2021. The company's cash, cash equivalents, and short-term investments totaled $228.3 million as of June 30, 2021, providing sufficient capital to advance clinical programs into late-stage development.

Enrollment continues in Phase 2b VOYAGE study evaluating VK2809 for the treatment of NASH.

Phase 1 study evaluating VK0214 achieved primary and secondary objectives; Phase 1b proof-of-concept trial in X-ALD patients underway.

Quarter-end cash of $228 million provides sufficient capital to advance clinical programs into late stage development.

VK2809-treated patients had significant reductions in plasma lipids, and median relative reductions in liver fat of up to approximately 60%.

EPS

-$0.2

Previous year: -$0.13

+53.8%

Cash and Equivalents

$8.83M

Previous year: $18.8M

-53.0%